Susanna Ulahannan
University of Oklahoma · OU Health Stephenson Cancer Center · Oklahoma University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Susanna Ulahannan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:01 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07829185 · Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic CancerUniversity of Oklahoma · recruiting · Pancreatic Ductal Adenocarcinoma (PDAC) · principal investigator
- Ph2NCT06129604 · Pilot Window of Opportunity Trial (POET)University of Oklahoma · active not recruiting · Colorectal Carcinoma (CRC), Endometrial Carcinoma (EC) · principal investigator
- Ph1/Ph2NCT04657068 · A Study of ART0380 for the Treatment of Advanced or Metastatic Solid TumorsArtios Pharma Ltd · recruiting · Advanced Cancer, Metastatic Cancer, Ovarian Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:01 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Protocol Review and Monitoring SystemP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · fiscal years 2026 · $85,605 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:01 UTC. The ranking covers the 200 most relevant of 18 PubMed records, and a shared surname and initials can bring in a namesake. All 18 on PubMed
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.J Hepatol · 2017662 citationsRCR 22.0
- The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.Nat Med · 2023137 citationsRCR 10.6
- 130 citationsRCR 14.0
- Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.Clin Cancer Res · 202278 citationsRCR 4.4
- Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma.Clin Cancer Res · 201774 citationsRCR 2.5
- A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors.Clin Cancer Res · 202262 citationsRCR 3.5
- 60 citationsRCR 1.7
- Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor.Clin Cancer Res · 202142 citationsRCR 2.1
- First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma.Mol Cancer Ther · 202330 citationsRCR 2.1
- A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer.Target Oncol · 202126 citationsRCR 1.2